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Background: The low toxicity of perfluorocarbons (PFCs), their high affinity for respiratory gases and their compatibility
with lung surfactant have made them useful candidates for treating respiratory diseases such as adult respiratory distress
syndrome. We report results for treating acute allergic and non-allergic bronchoconstriction in sheep using S-1226 (a gas
mixture containing carbon dioxide and small volumes of nebulized perflubron). The carbon dioxide, which is highly
soluble in perflubron, was used to relax airway smooth muscle.
Methods: Sheep previously sensitized to house dust mite (HDM) were challenged with HDM aerosols to induce early
asthmatic responses. At the maximal responses (characterised by an increase in lung resistance), the sheep were either
not treated or treated with one of the following; nebulized S-1226 (perflubron + 12% CO2), nebulized perflubron +medical
air, 12% CO2, salbutamol or medical air. Lung resistance was monitored for up to 20 minutes after cessation of treatment.
In additional naïve sheep, a segmental bronchus was pre-contracted with methacholine (MCh) and treated with nebulized
S-1226 administered via a bronchoscope catheter. Subsequent bronchodilatation was monitored by real time digital video
recording.
Results: Treatment with S-1226 for 2 minutes following HDM challenge resulted in a more rapid, more profound and
more prolonged decline in lung resistance compared with the other treatment interventions. Video bronchoscopy
showed an immediate and complete (within 5 seconds) re-opening of MCh-constricted airways following treatment with
S-1226.
Conclusions: S-1226 is a potent and rapid formulation for re-opening constricted airways. Its mechanism(s) of action are
unknown. The formulation has potential as a rescue treatment for acute severe asthma.
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Asthma is a common chronic disorder characterized by
airway hyper-responsiveness, bronchial smooth muscle
hypertrophy, increased mucus secretion, and airway in-
flammation [1,2] on a background of airway wall remod-
elling and mucous plugs [3,4]. Asthma is triggered by
many factors such as allergens (e.g., pollen, pet dander),
irritants (e.g., smoke), drugs, cold, exercise [5], and* Correspondence: fgreen@ucalgary.ca
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unless otherwise stated.upper respiratory tract infections [6]. Based on recent
trends, the worldwide prevalence of asthma may
increase from 300 million individuals currently to 400
million individuals by 2025 [7]. Healthcare costs of
asthma are considered to be among the highest associ-
ated with chronic disease [8,9]. In Canada, 59% of
asthma patients treated in general practice are estimated
to have uncontrolled disease [10]. Inhaled short acting
β2-agonists represent the most common front-line
emergency department treatment for acute exacerba-
tions due to their well-known rapid bronchodilatory ef-
fect [11–13] β2-agonists, while generally considered safe
may have significant side effects [14] and approximatelyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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front-line treatment with short acting β2-agonists and
ultimately require hospitalisation [15]. Furthermore, a
clinically significant proportion of asthma patients are
refractory to conventional treatments, posing a chal-
lenge for their management [16]. A new class of bron-
chodilators working through a different mechanism
would be a useful addition for treating acute asthma.
In acute severe asthma, conventional treatment with in-
haled β2 agonists may no longer be effective [11–13], as
the therapeutic aerosol may be unable to penetrate air-
ways obstructed by mucous plugs [4], increasing the risk
of sudden death [17]. Emergency treatment for asthma in-
cludes mechanical ventilation [15] which may cause injury
(barotrauma) to the ventilated segments of the lung [18].
Hence, a rapid non-invasive treatment for severe, life-
threatening asthma is needed.
Inhaled carbon dioxide is a known bronchodilator for
many mammalian species [19]. Hypercapnia has long been
known to relax airway smooth muscle in vitro [20,21],
whereas hypocapnia causes airway smooth muscle con-
traction [22]. Hyperventilation is a well known trigger of
asthma [23]. Studies by Fisher et al. [24] and Mc Fadden
et al. [25] indicate that low alveolar PCO2 (PACO2) may
be associated with an increase in airway tone in asthmatic
patients. By contrast hypercapnia (induced by a short cir-
cuiting CO2 absorber) has been shown to reduce airway
resistance in both healthy and asthmatic subjects [26]. Fi-
nally a study reported by Fisher and Hansen [27] showed
that inhalation of 6% CO2 over 4–5 minutes relieved exer-
cise induced airflow obstruction in young atopic asth-
matics at rest and during exercise.
Perfluorooctylbromide (perflubron) is a chemically
inert perfluorocarbon (PFC). It has a high solubility for
respiratory gases such as CO2 and O2 and a low surface
tension compatible with endogenous airway surfactant
[28–30]. It has been used in total and partial liquid
ventilation studies for treatment of ARDS [28]. In
addition, perflubron has been shown to reduce pul-
monary inflammation and injury through a variety of
actions [28,31–33]. The high density and low surface
tension of perflubron should also facilitate the penetra-
tion of obstructed airways and re-expansion of col-
lapsed lung [34].
There are no reported studies of PFC use in asthma.
However, its properties of gas transport for CO2 and O2,
low interfacial tension at the PFC-mucus interface, low
toxicity and anti-inflammatory properties [31–33,35]
make it a good candidate as a rescue therapy in life
threatening acute asthma. Recently perflubron aerosols
have been used to successfully treat acute lung injury in
an animal model [36,37].
The major challenge for treating acute severe asthma
is to open constricted airways rapidly enough to allowdelivery of conventional medication to the diseased
airways.
In this study we show that inhaled nebulized perflu-
bron + CO2 (S-1226) rapidly opens constricted airways
in an ovine model of allergic asthma using house dust
mite as allergen [38,39].
Methods
Experimental sheep
Female merino-cross farm-reared sheep aged 6 months
were used in the experiments described here. After the
sensitisation procedures (described below), sheep were
transported to Animal House Facility at Veterinary Sci-
ence, Parkville, Australia where they were kept in indoor
pens for all the procedures described in this report. On
arrival at the Animal House Facility all sheep were
treated with an antihelminthic to ensure that they were
parasite-free.
All experimental protocols used in this study were ap-
proved by the Animal Experimentation Ethics Commit-
tee at the University of Melbourne.
Drug source
Acetyl-β-methylcholine chloride (MCh) was from Sigma-
Aldrich, Stenhein, Germany and salbutamol sulphate solu-
tion was purchased from GSK Pty Ltd Australia. Gas mix-
ture (12% CO2 + 21% O2+ balance N2) was from CIG Pty
Ltd Australia.
Characterization of nebulized perflubron
Characterization of perflubron delivered by the Sidestream
nebulizer was conducted under cGMP conditions at
SolAero Ltd laboratory. Methods to characterize perflu-
bron aerosol were adapted from regulatory methods em-
bodied in the European Nebulizer Standard [40]. The
unique nature of perflubron required adaptation of
methods including incorporation of trace quantities (5%)
of a perflubron compatible non-volatile PFC which could
be assayed gravimetrically to determine both aerosol out-
put as well as particle size distributions. Aerosol output
was determined using a breath simulation (500 mL at
15 cycles per minute) and collecting released aerosol
representing the ‘inhaled aerosol’ on a pre-weighed 3M
electrostatic filter, subsequently allowing volatile perflu-
bron to dissipate and quantitatively weighing the non-
volatile PFC component. The residual weight gain was
then used to back calculate the original amount of depos-
ited aerosol. Pre- and Post- weights of nebulizers provided
the gross perflubron emitted, from which the analyzed
aerosol proportion could be subtracted to estimate the
proportion of perflubron in the vapor phase. Aerosol size
was determined using a Marple 298X cascade impactor
equipped with pre-weighed GF/A filters from which the
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determined to quantify size fractions.
House dust mite (HDM) sensitization and airway
challenges
Sheep 6 months of age were subcutaneously sensitized with
50 μg house dust mite (HDM) extract (Dermatophagoides
pteronyssinus; CSL Ltd, Parkville, VIC, Australia) mixed 1:1
in aluminum hydroxide [Al(OH)3] adjuvant. Injections of
1 ml HDM / Al(OH)3 were given on three occasions at
2 week intervals [38]. Levels of HDM-specific IgE (IgE-
HDM) were determined by enzyme-linked immunosorbent
assay (ELISA) of serum samples obtained from animals im-
mediately prior to, and 7 days after, HDM sensitization
[38,41]. Sheep were only selected for use in the study if they
had increased levels of HDM-specific IgE (IgE-HDM) ≥2-
fold above pre-sensitization values.
To induce pulmonary sensitization to HDM, all sheep
were given three inhalation challenges of aerosolised
HDM (1 mg/ml in 5 ml of phosphate buffered saline).
Lung function was recorded for one hour directly after the
aerosol HDM challenge. HDM aerosols were generated
with a medical nebulizer (Vitalair RapidNeb, Allersearch,
Vermont, Australia). The nebulizer was connected to a
dosimeter system consisting of a solenoid valve and a
source of compressed air (20 psi). The output of the nebu-
lizers was directed into a T-piece with one arm connected
to the inspiratory port of a mechanical ventilator (Intermed
Bear 2 – Adult Volume Ventilator, Bear Medical Systems,
Inc., Riverside, CA). HDM challenges were delivered at a
tidal volume of 500 mL and a rate of 20 breaths per minute
for 10 minutes.
Measurement of lung function
Data on lung function were obtained from all sheep using
established techniques [42]. Briefly, pressures and flow
were acquired from conscious unsedated sheep using a
National Instruments Data Acquisition (DAQ) system
with a Virtual Instrument programmed with Lab View®
(National Instruments, Austin, USA). The sheep were re-
strained in a body sheath and head restraining harness
tethered to a custom-made animal trolley. To measure
oesophageal pressures, a balloon pressure catheter was ad-
vanced through one nostril into the lower esophagus. To
assess tracheal pressures throughout the respiratory cycle
a cuffed endotracheal tube was placed into the trachea
and then a side-hole catheter was advanced 2 cm past the
distal end of the endotracheal tube. The oesophageal and
tracheal catheters were connected to differential transduc-
ers (Gaeltec 8 T, Gaeltec Ltd, Dunvegan, Scotland) to
measure oesophageal pressure (Poes) and airway pressures
(Paw) respectively. Transpulmonary pressure (Pl) was ob-
tained from Poes with respect to Paw. Airflow was mea-
sured via a pneumotachograph (Hans Rudolph Inc,Kansas City, USA) attached to the proximal end of the
endotracheal tube. Calibration and synchronization of the
gas transducers and pneumotachograph were performed
as described previously [43,44]. Lung dynamics were de-
termined by a modified Mead-Whittenberger method
[45]. Breath by breath analysis of flow and pleural pressure
(Ppl) was used to determine lung resistance (RL) from an
average of five breaths. Data from breaths which differed
by more than 20% in volume and more than 10% of the
breathing rate were rejected. Acquisition and detailed ana-
lysis of pulmonary physiological data were performed on
customized Lab View software developed by Koumoun-
douros et al. [42].
Treatment delivery
Treatments with nebulized S-1226, nebulized perflubron
and nebulized salbutamol were generated with a Side-
stream® nebulizer (Philips Respironics). The nebulizer
was connected to a dosimeter system consisting of a so-
lenoid valve and a source of compressed (20 psi driving
pressure) gas mixture (12% CO2, 21% O2 and 67% N2)
for S-1226 or compressed medical air (21% O2 and
79% N2) for perflubron and salbutamol. Treatments
were delivered at a tidal volume of 500 mL and a rate of
20 breaths per minute for 2 minutes. Treatments with
CO2 alone and medical air were performed following the
same protocol but with an empty nebulizer.
HDM challenge followed by treatment
Sheep (previously HDM sensitized) were challenged with
HDM aerosols to induce early phase asthmatic re-
sponses. At the peak of these responses (characterised
by an increase in lung resistance), the sheep were treated
for two minutes with one of six treatment groups listed
below. Lung resistance was monitored up to 20 minutes
following cessation of treatment.
1- S-1226: Nebulized perfluorooctylbromide
(perflubron) generated using a Sidestream® nebulizer
(Philips Respironics) and driven by a compressed gas
mixture containing 12% CO2, 21% O2 and balance
N2.
2- CO2 alone: Inhalation of a gas mixture containing
12% CO2, 21% O2 and balance N2.
3- Perflubron: Nebulized perflubron driven by
compressed medical air.
4- Salbutamol (1 mg/ml): Nebulized salbutamol driven
by compressed medical air.
5- Medical air: Inhalation of medical air
6- No treatment: room air
Video bronchoscopy
An unsensitised sheep was used in separate experiments
to visually assess the airway response to inhaled S-1226.
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scope digital camera following methacholine challenge.
To insure that the same airway was recorded throughout
the procedure, the upper region of the airway was tat-
tooed by injecting tissue dye using a transbronchial nee-
dle. The airway was then pre-contracted with an aerosol
of methacholine (MCh) delivered via a Trudell Ltd Pty
bronchoscope catheter, inserted into the biopsy port of
the bronchoscope. Doubling doses of methacholine were
nebulized directly into the lung segment (0.009, 0.018,
0.037 w/v) for 30 seconds with a 2 minute interval be-
tween methacholine doses until the airway was max-
imally constricted. The airway was then treated with
nebulized S-1226 delivered through a Trudell Pty Ltd
bronchoscope catheter and the effects video recorded in
real time. If the airway re-constricted, second and third
treatments were administered.
Data analysis
In each experiment several intervals were analysed:
Baseline, HDM-induced early phase response, and three
post-treatment periods (immediately, 1–10 minute and
10 to 20 minutes after treatment cessation). Means were
calculated for each interval and treatment effect was
expressed as percent decline of lung resistance.
Analysis of variance (ANOVA) was performed over
each time interval to determine if any of the treatment
groups performed better than any other. A two tailed
Dunnett’s post-hoc test was performed. This involved
separate analyses addressing two distinct questions. The
first: is S-1226 superior to no treatment, medical air
(negative control) or salbutamol (positive control). Sec-
ondly to determine which component of S-1226, CO2 or
perflubron contributed greater to its efficacy. Tests were
performed using GraphPad Prism version 5.00 and R
version 3.1.1 for windows. A p-value ≤ 0.05 was consid-
ered significant.
Results and discussion
Characterization of nebulized perflubron
Results from characterization of nebulized perflubron are
summarized in Table 1. The mean rate of perflubron deliv-







aerosol 1 minute mg
Inhaled p
Vapor 1 m
Exp#1 8.5 208 392
Exp#2 8.5 198 399
Nebulized perflubron was characterized in two separate experiments (exp#1 and ex
nebulizer with active venturi closed. Nebulized perflubron liquid was determined to
predominant physical form (means: 395 mg/min vapour vs 203 mg/min aerosol). Th
and fractionated using a Marple 298X cascade impactor. The nebulized perflubron
distribution, Figure 4) having a Mass Median Aerodynamic Diameter (MMAD) of 1.1consisted of aerosol with the remaining 395 mg/minute
was estimated to be in vapor form – thus the majority
(approximately 2/3 of the nebulized perflubron) was deliv-
ered in vapor form. The perflubron which was delivered in
aerosol form demonstrated a relatively small particle size
distribution, with a Mass Median Aerodynamic Diameter
(MMAD) of 1.1 um, with a Geometric Standard Deviation
(GSD) of 2.5 (Table 1). The perflubron aerosol size distribu-
tions obtained from the Sidestream nebulizer are shown in
Figure 1.
The characterization of nebulized perflubron demon-
strated that the majority of the nebulized perflubron
existed in the vapor form while the remaining propor-
tion of aerosol existed as a relatively fine aerosol with an
MMAD of 1.1 um. We infer that perflubron as vapor
and aerosol, as well as CO2 gas component of inhaled S-
1226, would rapidly distribute throughout the respira-
tory tract.
HDM challenge followed by treatment
Sensitized and HDM challenged sheep treated with S-1226
for 2 minutes during the peak of the early phase allergic re-
sponse showed an immediate decline in lung resistance in
all animals following HDM challenge (Figure 2).
Treatment with S-1226 compared to the other arms of
the study are shown in Figure 3. Lung resistance de-
clined by 50.1% ± 5.5, 47.2% ± 6.2 and 51.8% ± 8.3 (mean
± SE) immediately, 1 to 10 minutes and 10 to 20 minutes
after treatment with S-1226 respectively. Treatment with
12% CO2 resulted in declines in lung resistance of
36.9% ± 6.8, 20.6% ± 12.0 and 24.3% ± 28.4 (mean ± SE)
immediately, 1 to 10 minutes and 10 to 20 minutes after
treatment respectively. Treatment with perflubron +
medical air resulted in declines in lung resistance of
24.8% ± 7.5, −1.3% ± 10.7 and −7.2% ± 5.1 (mean ± SE)
immediately, 1 to 10 minutes and 10 to 20 minutes after
treatment respectively. Treatment with salbutamol re-
sulted in declines in lung resistance of 31.3% ± 6.8,
15.3% ± 7.1 and 14.3% ± 9.6 (mean ± SE) immediately, 1
to 10 minutes and 10 to 20 minutes after treatment
respectively. Following inhalation of medical air, lung
resistance declined by 23.1% ± 9.7, 16.0% ± 10.8 and
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Figure 1 Sidestream nebulizer aerosol size distribution. Aerosol size is on the X-axis is plotted against the normative and cumulative underside
aerosol distributions. The blue boxes profile the normative size distribution of nebulized perflubron, the near symmetry suggests a log-normal
distribution of aerosol particles. The red squares plot the same data but as a cumulative size distribution of particle size against cumulative undersize
%. The cumulative size distribution is used to interpolate the MMAD as the particle size at 50% of the cumulative mass – in this case the MMAD is 1.1
um. The Geometric Standard Deviation (GSD) of the MMAD is calculated using the intercepts at 15.8% and 84.1% (approximated by grey lines in
Figure) using the formula GSD = sq rt (size 84.1um / size 15.8 um).
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resistance measured following HDM challenge with no
treatment decreased by 1.9% ± 4.7, 24.4% ± 4.2 (mean ±
SE) at 1 to 10 minutes and 10 to 20 minutes after treat-
ment respectively.
Inhalation of nebulized S-1226 caused a rapid and sus-
tained decrease in lung resistance during the early phase
asthmatic response which was significantly greater than
no treatment at 1–10 minutes (p = 0.002) and significantly
greater than medical air immediately, 1–10 minutes andFigure 2 Effect of S-1226 on lung resistance in the sheep model of as
9 different sheep. The treatment was delivered for 2 minutes and lung resi
minutes after treatment cessation. All nine sheep showed an immediate an
given at the peak of the early phase response to inhaled allergen (HDM).10–20 minutes after treatment (p = 0.027, 0.018 and 0.039
respectively). The effect of S-1226 was significantly greater
than salbutamol 1–10 minutes and 10–20 minutes after
treatment (p= 0.025 and 0.046 respectively). S-1226 showed
a significantly greater decline in lung resistance than perflu-
bron alone immediately, 1–10 minutes and 10–20 minutes
after treatment (p= 0.019, 0.002 and 0.012 respectively). Fi-
nally, the effect of S-1226 was stronger but not significantly
different from CO2 alone immediately, 1–10 minutes and
10–20 minutes after treatment (p= 0.329, 0.124 and 0.319thma. Changes in lung resistance following treatment with S-1226 in
stance was measured immediately, and at 1–10 minutes and 10–20
d sustained decline in lung resistance following S-1226 treatment
Figure 3 Comparison between S-1226 and other bronchodilators in the sheep model of asthma. This figure shows the % decline in lung
resistance following treatment with S-1226, 12% CO2, perflubron, salbutamol, medical air or no treatment in HDM challenged sheep. Measurements
were taken immediately, 1–10 minutes and 10–20 minutes after treatment. Treatment with S-1226 showed significant and sustained declines in lung
resistance compared to medical air or no treatment. In addition S-1226 showed a significantly greater decline in lung resistance compared to
salbutamol. P-values show significant difference from S-1226; *p <0.05, # p≤ 0.01.
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shorter-lasting than the decline observed with S-1226.
Video-bronchoscopy of S-1226 treatment following
MCh challenge
The rapidity of the effect was demonstrated by video-
bronchoscopy. MCh challenge resulted in rapid constric-
tion of the segmental and subsegmental bronchi. Without
treatment the airway narrowing lasted for at least
20 minutes before a slow natural recovery. Following
treatment with a spray of S-1226 there was an immediate
re-opening (within 5 seconds) of the MCh-constrictedFigure 4 Video bronchoscopy of the effect of S-1226. Bronchoscopic s
initiating treatment with nebulized S-1226 (arrow heads indicate tissue dyeairway (Figure 4). A video recording of this treatment ef-
fect can be viewed online under Additional file 1. The ef-
fect was sustained during the delivery of S-1226 and up to
1 minute after treatment cessation. After that the airway
began to re-constrict. Second and third treatments with S-
1226 had identical effects.
Potential mechanisms of action
Our study did not attempt to determine the mechanism
of action of S-1226. The bronchodilatory effect of CO2
has been demonstrated in many mammalian species in-
cluding cats, rats dogs [19,22] as well as sheep andtill images of sheep airways pre and post MCh and seconds after
). The video presentation is available online under Additional file 1.
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operate through several distinct mechanisms.
The first mechanism is through a direct physiologic
relaxant effect of CO2 on airway smooth muscle [20–
22]. The way(s) in which CO2 regulates bronchial
smooth muscle tone is not fully understood. Recent
in vitro data indicates that part of this effect is mediated
by pH dependent and part by pH independent but epi-
thelium dependent mechanisms [22]. Studies in vivo in-
dicate the response (in rats) to inhaled CO2 does not
require adrenergic pathways [46]. Fisher and Hansen
[27] showed in their study of exercise induced asthma
that cholinergic pathways were not involved in the
bronchodilatory effects of inhaled CO2. Bronchodilator
drugs that use β- adrenergic and cholinergic pathways
form the current basis for treating obstructive lung
disease.
Inhaled carbon dioxide (5, 10 and 15%) has been shown
to reduce total lung resistance induced by intravenous his-
tamine, acetylcholine and serotonin in dogs, cats and rats
[19]. Inhaled CO2 has also been shown to reduce total
lung resistance induced by pulmonary artery occlusion in
cats and dogs [19]. All species studied responded to CO2
but there were small differences in response to the differ-
ent broncho-constricting agents between species.
Studies by Ingram and colleagues [47] suggest that the
bronchodilatory effect of CO2 may be independent of
blood PCO2. They studied the effect of varying airway
and arterial PCO2 on airway tone in dogs. They showed
that low airway PCO2 combined with high arterial PCO2
resulted in a large increase in airway resistance [47].
These findings indicate that CO2 may have unique prop-
erties when delivered through the airways and supports
the previously cited in vitro work that airway epithelium
plays a part in the relaxant response [22]. Finally the
rapidity of the response as seen in the sheep video indi-
cates that neural mechanisms are involved. The non-
adrenergic-non cholinergic (NANC) pathways are the
best candidates for this effect. The NANC system has
both broncho-constrictive and bronchodilator compo-
nents [48]. CO2 alone or S-1226 may activate the
bronchodilatory pathways or inhibit the broncho-
constrictive pathways. Further work is required to ad-
dress these questions.
The second mechanism may enhance delivery of CO2
to the airways. It could do this in several ways; first sus-
tained release of CO2 dissolved in perflubron droplets as
the droplets evaporate may explain the temporal syner-
gism observed with the combination treatment. Second,
because much of S-1226 is in gaseous form, it will be de-
livered rapidly into obstructed airways by diffusion and
possibly through collateral ventilation.
The third mechanism whereby this combination treat-
ment may work is by facilitating penetration andlubrication of mucus plugs, thus enhancing muco-
ciliary clearance. We recently reported, using an in vitro
system, that mucin plug clearance was significantly en-
hanced by perflubron [49].
S-1226 may also lower the surface tension in the in-
flamed airways. It has been shown that the normal air-
way is lined by a thin film of endogenous surfactant with
a low surface tension [50]. This film is important for
maintaining small airway patency at low lung volumes
[51] and is abnormal in asthma [52,53].
Finally, carbon dioxide and perfluorocarbons may also
be beneficial for their anti-inflammatory properties. Per-
flubron given in vitro or during partial liquid ventilation
exerts an anti-inflammatory effect on alveolar cells [54],
decreases white blood cell counts, [54,55] and the pro-
inflammatory cytokines IL-1 and IL-6. Perflubron also
increases release of the anti-inflammatory chemokine
IL-10 [54].
Strengths and limitations of the animal model
Like with most experimental systems, large animal models
of allergic airway disease have both strengths, and also
limitations, which need to be recognised when evaluating
new therapies for asthma [56–58]. For example, clinically
efficacious anti-asthma drugs such as leukotriene LTE4 re-
ceptor antagonists, cromolyn and corticosteroids have all
been successfully tested in the sheep model of asthma
[59]. The success of these drugs is in contrast to the test-
ing of platelet activated factor (PAF) antagonist therapies
in sheep. PAF antagonists were shown to alleviate allergic
airway responses in sheep [60], however the positive out-
come with these treatments in sheep did not translate to
humans giving negative results in clinical trials [61].
Nevertheless, sheep are an appropriate species to investi-
gate the efficacy of the bronchodilator reported here for a
number of important reasons. Firstly, the sheep respira-
tory system is at least comparable to the human system
with respect to lung size, lung anatomy and morphology,
and the pharmacological and physiological parameters of
the ovine lung [57–59]. Pertinent to this study, as the
mechanism of the bronchodilator most likely involves
both the airway smooth muscle and the intact airway epi-
thelium [22], is that the arrangement and morphology of
ovine airway epithelium [62] and airway smooth muscle
down the tracheo-bronchial tree [57] is functionally simi-
lar to that observed in human lungs. Thus, the broncho-
dilator interactions we report here for the sheep model
could reasonably translate to the human lung. The other
major asset of the sheep model for examining broncho-
dilator effectiveness relates to the docile nature of sheep,
which allows experiments to be ethically conducted in
unsedated and unanaesthetised animals [59,63]. These an-
aesthetic and/or sedation agents, if administered as is ne-
cessary for behavioural reasons in most other animal
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thus mask, the bronchodilator responses.
In summary, we provide evidence that treatment with
inhaled S-1226 delivered as an aerosol/gas mixture may
play an important role in the treatment of acute asthma
attacks. We show that perflubron combined with 12%
CO2 is a potent airway smooth muscle relaxant in this
ovine model of allergic asthma. The response to the
combination treatment was rapid and exceeded treat-
ment with medical air (negative control) and salbutamol
(positive control) in both amplitude and temporal com-
ponents. Further work is required to fully evaluate the
mechanism(s) of action of this novel therapy.
Additional file
Additional file 1: Video clip description: the black dot is the stain
from the tissue dye. The partially occluded airway that is in the center
of the screen begins to dilate immediately after the treatment starts (with
the click sound on the video). Note that the adjacent smaller, completely
occluded, airways also re-opened with treatment.
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